BACKGROUND: Tissue inhibitors of metalloproteinase (TIMPs) have at least 2 different functions. They inhibit the catalytic activity of matrix metalloproteinases, and they act as growth factors. METHODS: Pretreatment ethylenediamine tetracetic acid plasma TIMP-1 was assayed from 251 patients who were enrolled in a Phase III, second-line, hormone therapy trial, and from a control group of 50 healthy, postmenopausal women by using the TIMP-1 enzyme-linked immunosorbent assay. RESULTS: The plasma TIMP-1 levels from the postmenopausal control group (n = 50 women) were 201 +/- 86 ng/mL mean +/- standard deviation (range, 49-455 ng/mL). The upper limit of normal was defined as the mean +/- 2 standard deviations of the control group (373 ng/mL). Patient pretreatment plasma TIMP-1 levels ranged from 70 ng/mL to 982 ng/mL. Plasma TIMP-1 was elevated above the mean + 2 standard deviations of the control group (373 ng/mL) in 19 patients (7.6%). In univariate analysis, patients who had elevated versus normal plasma TIMP-1 levels had a reduced clinical benefit rate (CBR) (16% vs 42%; P = .03). The time to progression (TTP) (84 days vs 174 days; P < .0001) and overall survival (141 days vs 860 days; P = .0001) also were significantly shorter in patients who had elevated TIMP-1 levels. TTP and overall survival also were significantly shorter in patients who had higher TIMP-1 plasma levels when it was analyzed as a continuous variable. In multivariate analysis, elevated plasma TIMP-1 level remained a prognostic factor for reduced overall survival (P < .0001) along with elevated serum HER-2/neu (P < .0001) and the presence of visceral metastases (P = .008). CONCLUSIONS: Elevated pretreatment plasma levels of TIMP-1 predicted a decreased response to second-line hormone therapy and reduced survival in women with metastatic breast cancer. (c) 2007 American Cancer Society
RCT Entities:
BACKGROUND: Tissue inhibitors of metalloproteinase (TIMPs) have at least 2 different functions. They inhibit the catalytic activity of matrix metalloproteinases, and they act as growth factors. METHODS: Pretreatment ethylenediamine tetracetic acid plasma TIMP-1 was assayed from 251 patients who were enrolled in a Phase III, second-line, hormone therapy trial, and from a control group of 50 healthy, postmenopausal women by using the TIMP-1 enzyme-linked immunosorbent assay. RESULTS: The plasma TIMP-1 levels from the postmenopausal control group (n = 50 women) were 201 +/- 86 ng/mL mean +/- standard deviation (range, 49-455 ng/mL). The upper limit of normal was defined as the mean +/- 2 standard deviations of the control group (373 ng/mL). Patient pretreatment plasma TIMP-1 levels ranged from 70 ng/mL to 982 ng/mL. Plasma TIMP-1 was elevated above the mean + 2 standard deviations of the control group (373 ng/mL) in 19 patients (7.6%). In univariate analysis, patients who had elevated versus normal plasma TIMP-1 levels had a reduced clinical benefit rate (CBR) (16% vs 42%; P = .03). The time to progression (TTP) (84 days vs 174 days; P < .0001) and overall survival (141 days vs 860 days; P = .0001) also were significantly shorter in patients who had elevated TIMP-1 levels. TTP and overall survival also were significantly shorter in patients who had higher TIMP-1 plasma levels when it was analyzed as a continuous variable. In multivariate analysis, elevated plasma TIMP-1 level remained a prognostic factor for reduced overall survival (P < .0001) along with elevated serum HER-2/neu (P < .0001) and the presence of visceral metastases (P = .008). CONCLUSIONS: Elevated pretreatment plasma levels of TIMP-1 predicted a decreased response to second-line hormone therapy and reduced survival in women with metastatic breast cancer. (c) 2007 American Cancer Society
Authors: Christina Bjerre; Lena Vinther; Kirstine C Belling; Sidse Ø Würtz; Rachita Yadav; Ulrik Lademann; Olga Rigina; Khoa Nguyen Do; Henrik J Ditzel; Anne E Lykkesfeldt; Jun Wang; Henrik Bjørn Nielsen; Nils Brünner; Ramneek Gupta; Anne-Sofie Schrohl; Jan Stenvang Journal: Tumour Biol Date: 2013-07-24
Authors: Matthew Crocker; Sue Ashley; Ian Giddings; Vladimir Petrik; Anthea Hardcastle; Wynne Aherne; Andy Pearson; B Anthony Bell; Stergios Zacharoulis; Marios C Papadopoulos Journal: Neuro Oncol Date: 2010-12-16 Impact factor: 12.300
Authors: Russell J Schilder; Harsh B Pathak; Anna E Lokshin; Robert W Holloway; Ronald D Alvarez; Carol Aghajanian; Hua Min; Karthik Devarajan; Eric Ross; Charles W Drescher; Andrew K Godwin Journal: Gynecol Oncol Date: 2009-01-21 Impact factor: 5.482
Authors: Volkmar Müller; Sabine Riethdorf; Brigitte Rack; Wolfgang Janni; Peter A Fasching; Erich Solomayer; Bahriye Aktas; Sabine Kasimir-Bauer; Julia Zeitz; Klaus Pantel; Tanja Fehm Journal: Breast Cancer Res Date: 2011-07-11 Impact factor: 6.466
Authors: Anne-Sofie Schrohl; Maxime P Look; Marion E Meijer-van Gelder; John A Foekens; Nils Brünner Journal: BMC Cancer Date: 2009-09-10 Impact factor: 4.430
Authors: Lisa A Ridnour; Kimberly M Barasch; Alisha N Windhausen; Tiffany H Dorsey; Michael M Lizardo; Harris G Yfantis; Dong H Lee; Christopher H Switzer; Robert Y S Cheng; Julie L Heinecke; Ernst Brueggemann; Harry B Hines; Chand Khanna; Sharon A Glynn; Stefan Ambs; David A Wink Journal: PLoS One Date: 2012-09-05 Impact factor: 3.240